https://clinicaltrials.gov/ct2/show/NCT04283461

Lancet 395, 1845–1854 (2020)

The urgent need to develop a vaccine against SARs-CoV2 compressed the normal vaccine-development timeline to reach in-human clinical trials from several years to just over two months, and a vaccine developed by Moderna was the first to reach this stage in March.

In late May, CanSino Biologics was the first to publish their trial results of a vaccine against COVID-19 in a peer-reviewed journal. CanSino’s candidate is an adenoviral construct that expresses the SARS-CoV-2 spike glycoprotein. It was found to be immunogenic, with most of the 108 participants developing specific antibody and T cell responses. Although 81% of the immunized participants reported moderate adverse effects, no serious adverse reactions occurred. So far, no conclusive information on efficacy is available for CanSino’s, or any other, vaccine candidate.